2017 Archived Content

We are witnessing rapidly unfolding efforts to reinvigorate the antibacterial pipeline, improve antimicrobial stewardship and bring the multidrug microbial resistance under control. Industry, academia and government entities are working together on sustainable solutions for the antibiotic resistance crisis. Multidrug-resistant Gram-negative bacteria currently pose the biggest threat and attract the most attention from researchers and policy makers. Novel platforms, screening strategies and new drugs as well as new pathways for clinical development and market access are needed to overcome the current state of emergency associated with multidrug-resistant bacteria. Cambridge Healthtech Institute’s Fourth Annual Re-Entering Antibacterial Discovery and Development Summit is designed as a knowledge and experience exchange for the major stakeholders working in this important area. The Summit features two conferences, Antibacterial Discovery and Development (October 18-19) and Targeting Gram-Negative Pathogens (October 19-20), and several short courses.

Short Courses

Featured Speakers Include:

Eric Brown

Eric Brown, Ph.D., Professor, Biochemistry and Biomedical Sciences, McMaster University

Kim Lewis

Kim Lewis, Ph.D., University Distinguished Professor, Biology; Director of Antimicrobial Discovery Center, Biology, Northeastern University

Olga Lomovskaya

Olga Lomovskaya, Ph.D., Vice President, Infectious Diseases, The Medicines Company

Todd Black

Todd A. Black, Ph.D., Executive Director, Infectious Diseases, Basic Research, Merck Research Laboratories

David Hooper

David C. Hooper, M.D., Chief, Infection Control Unit, Massachusetts General Hospital

Ruben Tommasi

Ruben Tommasi, Ph.D., CSO, Entasis

Recommended Short Courses

Clinically Relevant Animal Modeling for the Evaluation of Novel Antibacterial Approaches
From “White Powder” to Drug: The Path from Antibacterial Discovery to the Clinic
Technologies to Assess Permeability in Gram Negative Bacteria